Search

Author/Creator Stienen, Sabine

1. A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors. (3rd August 2018)

Authors:
Kebenko, Maxim; Goebeler, Marie-Elisabeth; Wolf, Martin; Hasenburg, Annette; Seggewiss-Bernhardt, Ruth; Ritter, Barbara; Rautenberg, Beate; Atanackovic, Djordje; Kratzer, Andrea; Rottman, James B.; Friedrich, Matthias; Vieser, Eva; Elm, Stefanie; Patzak, Ingrid; Wessiepe, Dorothea; Stienen, Sabin...
Journal:
Oncoimmunology
Issue:
Volume 7:Number 8(2018)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. ATIM-49 (LTBK-01). AMG 596, A NOVEL ANTI-EGFRVIII BISPECIFIC T CELL ENGAGER (BITE®) MOLECULE FOR THE TREATMENT OF GLIOBLASTOMA (GBM): PLANNED INTERIM ANALYSIS IN RECURRENT GBM (RGBM). (22nd November 2019)

Authors:
Rosenthal, Mark A; Balana, Carmen; van Linde, Myra E; Sayehli, Cyrus; Fiedler, Walter M; Wermke, Martin; Massard, Christophe; Mellinghoff, Ingo K; Khasraw, Mustafa; Ang, Agnes; Rasmussen, Erik; Kast, Johannes; Stienen, Sabine; Cloughesy, Timothy F
Journal:
Neuro-oncology
Issue:
Volume 21(2019)Supplement 6
Page Start:
vi283
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗